M&A / Deals Roche places a $1bn bet on C4T degrader-antibody conjugates PharmaphorumRoche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaphorum Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T. M&A / DealsOncologyRead full story Post navigation Previous: Roche and C4 Therapeutics to advance degrader-antibody conjugates researchNext: GSK again pulls application for leucovorin, touted by FDA as potential autism treatment Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026